NCT02858310 2026-03-09
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
Clinical Trials
177 trialsNCT00026312 2026-03-05
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT04426669 2026-02-23
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
Intima Bioscience, Inc.
Phase 1/2 Completed
NCT01659151 2026-02-20
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02964078 2026-02-10
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01005745 2025-12-19
Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT01319565 2025-12-19
Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01701674 2025-12-19
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT00534469 2025-12-02
Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R
City of Hope Medical Center
Phase 2 Completed
NCT02775292 2025-07-30
NYM
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT00994643 2025-04-30
Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma
Thomas Jefferson University
Phase 2 Completed
NCT02278887 2025-03-10
TIL
The Netherlands Cancer Institute
Phase 3 Completed
NCT02876510 2025-02-04
ACTolog
Immatics US, Inc.
Phase 1 Completed
NCT02500576 2025-01-15
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02926053 2024-11-22
TIL Therapy for Metastatic Renal Cell Carcinoma
Herlev Hospital
Phase 1 Completed
NCT03318900 2024-11-07
T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03296137 2024-10-26
Adoptive Cell Therapy Across Cancer Diagnoses
Herlev Hospital
Phase 1/2 Completed
NCT01740557 2024-10-08
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04862767 2024-01-31
TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor
Autotelicbio
Phase 1 Completed
NCT00968760 2023-12-19
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT06152367 2023-11-30
Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients
University of Chile
Phase 1/2 Completed
NCT01823198 2023-11-07
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00617799 2023-10-10
Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma
University of Nebraska
Completed
NCT03215810 2023-07-24
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00003027 2023-06-22
Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT01288963 2023-06-15
IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma
Beth Israel Deaconess Medical Center
Completed
NCT03841110 2023-05-01
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed
NCT01993719 2023-01-18
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01807182 2022-11-10
Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT01700946 2022-09-28
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT02111850 2022-03-29
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00924326 2022-01-12
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00414765 2021-06-08
Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
Novartis
Phase 4 Completed
NCT01967823 2021-03-24
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02763475 2020-10-05
NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents
Instituto de Investigación Hospital Universitario La Paz
Phase 2 Completed
NCT01266603 2020-02-19
High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02379195 2020-01-22
Peginterferon and TIL Therapy for Metastatic Melanoma
Herlev Hospital
Phase 1/2 Completed
NCT01550367 2020-01-02
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
University of Pittsburgh
Phase 1/2 Completed
NCT00304460 2019-12-12
Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01883323 2019-11-08
Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma
University Health Network, Toronto
Phase 2 Completed
NCT00853021 2019-06-05
Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01603212 2019-05-21
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01258855 2019-05-10
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00002787 2019-05-06
Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation
Fred Hutchinson Cancer Center
Phase 1 Completed
NCT00002746 2019-02-27
Interleukin-2 in Treating Patients With Myelodysplastic Syndrome
University of Washington
Phase 1 Completed
NCT00470015 2019-02-19
Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma
Mayo Clinic
Phase 1 Completed
NCT00085436 2018-06-26
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT01585428 2018-03-07
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00274846 2017-12-28
Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00303667 2017-12-28
Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Phase 1/2 Completed